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Abstract 
Kisspeptin (also termed as metastin) is a peptide that has been isolated from the human placenta as the 
cognate ligand of the G-protein-coupled receptor KISS1 receptor (KISS1R, also termed as GPR54). 
However, its physiological functions were not fully investigated when kisspeptin was identified. In 
this thesis, through the functional analysis in rats, I first show that the subcutaneous administration of 
kisspeptin or its agonist analogues activates the hypothalamic gonadotropin releasing hormone 
(GnRH) neurons, associated with robust elevations in plasma follicle stimulating hormone (FSH) and 
luteinizing hormone (LH) levels. These results suggest that kisspeptin is regarded as a newly 
characterized regulator of GnRH and gonadotropin release in the hypothalamic-pituitary-gonadal 
(HPG) axis. I then study the effect of continuous subcutaneous administration of kisspeptin agonist 
analogues on the HPG-function in male rats, and demonstrate that the continuous administration 
results in abrupt reductions of sex hormone levels including testosterone. Mechanistic studies suggest 
that continuous administration of kisspeptin analogues disrupts endogenous kisspeptin signals to 
suppress intrinsic GnRH pulses by desensitization of KISS1R on GnRH neurons. I further investigate 
the potential application of kisspeptin agonist analogues, and demonstrate continuous administration 
of kisspeptin agonist analogues leads to rapid and profound reductions in testosterone levels and also 
in testosterone-dependent organs' weight including prostate, seminal vesicles, and testes. In addition, 
in a pre-clinical rat model of androgen dependent prostate cancer, the JDCaP rat model, continuous 
administration of kisspeptin agonist rapidly decreased plasma prostate specific antigen (PSA) levels, 
which is clinically relevant prostate cancer marker. Thus, my thesis demonstrates that kisspeptin is a 
novel and perhaps physiologically meaningful GnRH secretagogue and kisspeptin agonist analogues 
may hold promise as a novel therapeutic approach for suppressing reproductive functions and 
hormone-dependent diseases such as prostate cancer.    
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Abbreviations 
 
ADT androgen deprivation therapy 
AR androgen receptor 
ARC arcuate nucleus 
AVPV anteroventral periventricular nucleus 
CHO Chinese hamster ovary 
CI confidence interval 
DMSO dimethylsulfoxide 
DW distilled water 
E2 estradiol 
EC50 half maximal effective concentration 
eCG equine chorionic gonadotropin 
EIA enzymeimmuno assay 
ER estrogen receptor 
FSH follicle stimulating hormone 
GnRH gonadotropin releasing hormone 
GPCR G-protein coupled receptor 
hCG human chorionic gonadotropin 
IC50 half maximal inhibitory concentration 
IHH idiopathic hypogonadotropic hypogonadism 
KISS1R KISS1 receptor 
Kp-10 kisspeptin-10 
Kp-54 kisspeptin-54 
LC-MS/MS liquid chromatography-tandem mass spectrometry 
LH luteinizing hormone 
ME median eminence 
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MUA multiunit electrical activity 
MW molecular weight 
NMDA N-methyl-D-aspartate 
ORX orchiectomy 
OVLT organum vasculosum of the lamina terminalis 
P4 progesterone 
POA preoptic area 
PVN paraventricular nucleus 
RIA radioimmuno assay 
SON supraoptic nucleus 
T testosterone  
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Introduction 
Reproductive function in mammals is regulated by the three critical components, hypothalamus, 
pituitary, and gonad. In 1940's Harris et al. proposed the fundamental concept of the 
neuroendocrinology (Charlton, 2008). Historically it had been known that sexual functions including 
estrus cyclicity and ovulations were regulated by the hypothalamus and pituitary but little 
understandings about its precise mechanism had not been elucidated. The simplest plausible 
mechanism was the direct neural innervation from the hypothalamus to the pituitary and/or gonads but 
such kind of anatomical evidences only existed in oxytocin and vasopressin, both of these are secreted 
from the nerve terminals in the posterior pituitary innervated from the hypothalamus. Harris et al. 
addressed this question with surgical approach and demonstrated that a portal vein between the 
hypothalamus and the pituitary efficiently conveyed the substances released from the hypothalamic 
nerve terminals to the pituitary (Charlton, 2008). The actual substance released from the 
hypothalamus had not been identified until early 1970's by Schally et al. and Guillemin et al. (Schally, 
1999). They independently identified a peptide sequence of gonadotropin releasing hormone (GnRH, 
also termed as luteinizing hormone releasing hormone or LHRH) from pigs and sheep as a critical 
peptide in stimulating follicle stimulating hormone (FSH) and luteinizing hormone (LH) from the 
pituitary. Subsequently the peptide structure of GnRH in other species including human were 
identified with highly conserved structure. 
In rats and mice, the majority of GnRH neurons exist in preoptic area (POA) within the 
posterior hypothalamus, and the neurons project to median eminence (ME) close to the arcuate 
nucleus (ARC) region (Fig. 1). GnRH is released from the ME to the hypothalamic-pituitary portal 
vein, which eventually conveys GnRH to the pituitary. There are two modes of GnRH release; GnRH 
pulses and GnRH surge (Maeda & Tsukamura, 2011). The physiological importance of pulsatile 
GnRH release was first demonstrated by Belchetx et al. in 1978 (Belchetz et al., 1978). They tested 
intermittent and continuous GnRH administration in rhesus monkeys with hypothalamic lesions, and 
demonstrated that intermittent GnRH administration, once per hour, elevated serum gonadotropin 
levels while the continuous infusion suppressed the gonadotropin release, which is known as 
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"desensitization" of the pituitary to the continuous exposure to GnRH. Following this observation, 
pulsatile GnRH release was finally demonstrated in domestic animals (eg. ewes and goats) in which 
the hypothalamic-pituitary portal blood was collected by excellent surgical technique (Tanaka et al., 
1997). Importantly, the pulsatile GnRH release into the portal blood was completely paralleled to the 
pulsatile LH release from the pituitary, suggesting GnRH pulses are the critical driver of LH pulses. 
Furthermore, pulsatile neural activity, called multiple unit activity (MUA) volley, was observed by 
means of electrodes implanted into the basal hypothalamus, and this MUA volley was also completely 
paralleled to pulsatile LH release (Mori et al., 1991; Cardenas et al., 1993). These evidences 
demonstrated that GnRH and LH pulses were regulated by pulsatile neural activity around the area of 
basal hypothalamus. On the other hand, the other mode of GnRH release, GnRH surge, is only 
observed in female animals, and this leads to pre-ovulatory LH surge and subsequently ovulation. The 
LH surge is associated with the strong activation of the GnRH neurons, as evidenced by c-Fos protein 
expressions within the GnRH neurons (Lee et al., 1990; Attardi et al., 1997). 
Both GnRH/LH pulses and surge are under control of gonadal steroid hormones, termed 
steroid hormonal feedback mechanism (Maeda & Tsukamura, 2011). GnRH/LH pulses are observed 
both in males and females, where elevations in circulating testosterone or estradiol levels lead to 
suppression of the GnRH/LH release (negative feedback). On the other hand, preovulatory GnRH/LH 
surge is triggered when ovarian follicles are maturated enough associated with apparent elevations in 
circulating estradiol levels (positive feedback). These steroidal positive and negative feedback 
systems have been widely acknowledged while its precise mechanism, especially the responsible 
neurons were remained to be elucidated for long time. Given that GnRH neurons do not express 
steroid hormone receptors (estrogen receptor alpha or ERa etc.), the existence of GnRH afferents 
which critically control GnRH neural activity and release have been suggested (Nishihara et al., 1999) 
(Fig. 1). As shown in Fig. 1, the GnRH neuronal body exists within the hypothalamic region of the 
preoptic area (POA), and the GnRH neurons project their nerve terminals to the median eminence 
(ME). Several experimental approaches, such as surgical denervation or local estrogen implantation, 
had revealed that the neurons responsible for GnRH/LH surge generation exist within the region of 
anteroventral periventricular nucleus (AVPV), while the neurons responsible for GnRH/LH pulses 
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exist within the region of ARC. Several research activities had tried to identify these GnRH/LH surge 
and pulse generators, but still remained to be elucidated (Nishihara et al., 1999). 
Kisspeptin is the cognate ligand of a G-protein coupled receptor (GPCR) KISS1R (also 
termed as GPR54) (Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001). Since kisspeptin is a 
gene product of the human metastasis suppressor gene, KISS1(Lee et al., 1996; Lee & Welch, 1997a; 
b), earlier studies on kisspeptin were focused on its activity as a tumor metastasis suppressor (Hori et 
al., 2001; Ohtaki et al., 2001; Stafford et al., 2002). Actually kisspeptin significantly suppressed 
cellular motility of KISS1R-expressing CHO cells in vitro and tumor metastasis of 
KISS1R-expressing melanoma in vivo, while its physiological role was not well understood (Hori et 
al., 2001; Ohtaki et al., 2001). KISS1 gene encodes a 145-amino acid precursor polypeptides, which is 
further enzymatically cleaved into a mature 54-amino acid peptides, Kp-54, with C-terminally 
amidated modification (Ohtaki et al., 2001). Within the 54-amino acid sequence, its C-terminal 10 
amino acid sequence, Kp-10, is critical in associating and activating KISS1R. This Kp-10 sequence is 
well conserved in vertebrates including fish, frogs, rodents, monkeys, and human (Table 1).  
 
 Schematic Illustration of the Hypothalamic-Pituitary-Gonadal Axis (Rodent Model) Fig. 1
The majorities of GnRH neural perikarya exist in the POA region, and project their neural terminals to 
the ME, where GnRH is released into the portal blood. There are two modes of GnRH release, GnRH 
pulses and GnRH surges. The GnRH pulses are common both in males and females, and controlling 
steroidogenesis, spermatogenesis, and follicular maturations. GnRH pulses are negatively controlled 
by gonadal steroid hormones (negative feedback), and the historical evidences have suggested some 
neurons within the ARC region receive this negative feedback signals. On the other hand, GnRH 
surge is observed exclusively in females and triggers ovulation in response to estradiol positive 
feedback. Historical evidences have suggested some neurons within the AVPV region receive this 
positive feedback signals. See text in detail.  
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Table 1 Putative Kisspeptin-10 Sequences 
Bold and shaded letters indicate conserved sequences across species. 
 
In this thesis, I first focus on investigating potential physiological functions of kisspeptin in 
reproductive axis in rats, and demonstrate peripherally administered kisspeptin induces ovulation 
associated with the robust elevations in plasma gonadotropins (FSH and LH). Furthermore, I focus the 
mechanism underlying the induction of gonadotropin-release by kisspeptin with the aid of a 
gonadotropin-releasing hormone (GnRH) antagonist Cetrorelix, c-Fos and GnRH double-labeling 
immunohistochemistry, and the primary culture of rat anterior pituitary cells.  
Following my first study, several evidences have shown that kisspeptin/KISS1R system is a 
key regulator of GnRH release from the hypothalamic GnRH neurons. In 2003, inactivating mutations 
in the KISS1R gene from idiopathic hypogonadotropic hypogonadism (IHH) patients were reported, as 
well as the murine phenotype of defective onset of puberty in mice lacking the Kiss1r gene (de Roux et 
al., 2003; Funes et al., 2003; Seminara et al., 2003). Several groups have demonstrated that, in 
accordance with my study in Chapter 1, central or peripheral bolus administration of kisspeptin 
resulted in marked GnRH and gonadotropin release in several species including human (Gottsch et al., 
2004; Irwig et al., 2004; Thompson et al., 2004; Dhillo et al., 2005). It is currently well accepted that 
kisspeptin directly activates GnRH neurons as evidenced by: (a) kisspeptin administration induces 
c-Fos immunoreactivity, a marker of neuronal activity (Kovacs, 1998), in GnRH neurons as shown in 
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this Thesis Chapter 1 and by Irwig et al. (Irwig et al., 2004); (b) GnRH neurons express Kiss1r 
promoter activity (Irwig et al., 2004; Messager et al., 2005); and (c) ex-vivo cultured GnRH neurons 
are depolarized following exposure to kisspeptin (Han et al., 2005; Liu et al., 2008; Pielecka-Fortuna 
et al., 2008). Finally, while the exact site of action of kisspeptin within the hypothalamus has not been 
fully elucidated, both synaptic and nonsynaptic associations of kisspeptin neurons with GnRH neurons, 
specifically in the region of the preoptic area and median eminence, respectively, have been identified 
by immunohistochemistry (IHC) as potential sites of action (Kinoshita et al., 2005; Clarkson & 
Herbison, 2006; Ramaswamy et al., 2008). 
As described above, acute administration of kisspeptin increases GnRH and gonadotropin 
levels and activates the reproductive system. In contrast, several groups have reported that chronic 
administration of kisspeptin results in attenuation of pituitary or gonadal function in rats (Thompson et 
al., 2006), monkeys (Seminara et al., 2006; Ramaswamy et al., 2007), and women (Jayasena et al., 
2010). Thus, the kisspeptin/KISS1R system can be considered a rational target for therapeutic 
regulation of reproductive functions. Although the N-terminally truncated human Kp-10 polypeptide is 
responsible for receptor binding and agonistic activity for KISS1R in vitro (Ohtaki et al., 2001), high 
susceptibility of Kp-10 to cleavage enzymes in vivo results in a short half-life which limits its potential 
use as a clinical therapeutic agent (Asami et al., 2012a; Asami et al., 2012b; Asami et al., 2013; Asami 
et al., 2014). Asami et al. have developed several analogue peptides of Kp-10 including KISS1-305, 
TAK-448, and TAK-683 (Asami et al., 2012a; Asami et al., 2012b; Asami et al., 2013; Asami et al., 
2014). KISS1-305 is a prototype peptide that resists plasma protease degradation but has sub-optimal 
KISS1R agonistic activity in vitro; TAK-448 and TAK-683 has good protease resistance and retains 
potent agonist activity comparable to Kp-10.  
In the second part of this Thesis, I study the potential clinical application of kisspeptin agonist 
analogues. Prostate cancer is the second most common cancer in the world (Jemal et al., 2011). Since 
Huggins and Hodges first proposed hormonal therapy to treat prostate cancer in 1941 (Huggins & 
Hodges, 1941), testosterone-lowering therapy has been the mainstay for prostate cancer treatment. 
Though the majority of prostate cancer is diagnosed as localized disease and curative treatments such 
as radical prostatectomy are standard, patients with metastatic prostate cancer are encouraged to 
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receive androgen deprivation therapy such as bilateral orchiectomy (ORX) or gonadotropin-releasing 
hormone (GnRH) analogue-based therapy. Currently, continuous administration of GnRH analogues, 
such as leuprolide, is the mainstay of treatment for prostate cancer. Therapy with GnRH analogues is 
initially associated with substantial testosterone elevation especially during the first week of therapy 
(Bubley, 2001). This is followed by desensitization of the pituitary, which eventually leads to a 
decrease in testosterone levels. To explore the pharmacodynamic effects of kisspeptin analogues, I 
compared the effect of repetitive (once daily) or continuous administration of TAK-448 and TAK-683 
with that of leuprolide on plasma testosterone levels as well as the weights of the reproductive organs 
in adult male Sprague-Dawley rats. I also evaluated the therapeutic potential of TAK-683, as a 
representative of kisspeptin agonist analogue, in a preclinical rat model of androgen-dependent human 
prostate cancer JDCaP (Kimura et al., 2009) by measuring serum prostate specific antigen (PSA) 
levels as a biomarker of antitumor activity. 
Furthermore, I investigated the mechanism of action of testosterone-lowering effect with these 
agents by (a) evaluating their effects on pituitary and hypothalamic responsiveness; (b) assessing the 
impact of chronic administration on the expression of Kiss1, Kiss1r, and Gnrh mRNA; and (c) 
determining GnRH peptide content in the hypothalamus as well as FSH and LH expression in the 
pituitary. My findings reveal that chronic administration of these kisspeptin analogues desensitizes 
GnRH neurons to endogenous kisspeptin input and reduces hypothalamic GnRH content. Together, 
these effects combine to suppress HPG function and consequently lower circulating concentrations of T. 
These results are discussed in relation to their impact on the elucidation of the biological and cellular 
processes that influence the control of the HPG axis as well as the pharmacological effects of these 
analogues on the control of T concentrations in plasma. 
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Materials and Methods 
Materials 
Human Kp-54, KISS1-305 ([D-Tyr
46
,D-Pya(4)
47
,azaGly
51
,Arg(Me)
53
] metastin(46-54), molecular 
weight [MW]: 1165.3), TAK-448 (Ac-[D-Tyr
46
,Hyp
47
,Thr
49
, 
azaGly
51
,Arg(Me)
53
,Trp
54
]metastin(46-54), MW: 1225.4), TAK-683 (Ac-[D-Tyr
46
, 
D-Trp
47
,Thr
49
,azaGly
51
,Arg(Me)
53
, Trp
54
]metastin(46-54), MW: 1298.5) (Asami et al., 2013), and 
leuprolide acetate (MW: 1209.40 as acetate-free form) were synthesized Takeda Pharmaceutical 
Company Limited (Osaka, Japan). eCG and hCG (Teikoku Hormone MFG, Tokyo, Japan), synthetic 
GnRH peptide (Peptide Institute, Osaka, Japan), GnRH antagonist Cetrorelix (ANASPEC, San José, 
USA), DNase I, pancreatin, fetal calf serum (FCS), and 17-β estradiol (Sigma-Aldrich, St. Louis, MO), 
Collagenase A (Roche Diagnostics, IN, USA), Dulbecco’s modified Eagle’s medium (DMEM, with or 
without phenol red, Invitrogen, CA, USA), and charcoal/dextran treated FCS (HyClone, UT, USA) 
were used in vivo and in vitro experiments. Osmotic ALZET mini-pumps (Model 2001 or 2004) were 
from Durect Co. (Cupertino, CA). Other general reagents were dimethyl sulfoxide (DMSO, 
Sigma-Aldrich, St. Louis, MO), aprotinin (Trasylol™, Bayer HealthCare Pharmaceuticals, Leverkusen, 
Germany), and EDTA-2Na (Dojindo Laboratories, Kumamoto, Japan). Rat FSH (rFSH-RP-2) and LH 
(rLH-RP-3) as reference peptides, and radioimmunoassay (RIA) sets were obtained from the National 
Hormone & Peptide Program (NHPP), National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), and Dr. A. F. Parlow (Harbor-UCLA Medical Center, Los Angeles, CA). A 
commercially available rat LH kit (rat LH [
125
I] assay system, GE Healthcare UK Ltd, Buckinghamshire, 
UK) was also used when specified. The T RIA and GnRH RIA kits were obtained from Siemens 
Healthcare Diagnostics Inc. (Deerfield, IL) and Peninsula Laboratories (San Carlos, CA), respectively.  
 
Animals 
Adult male Wistar rats, immature female Wistar rats, and adult male Sprague-Dawley Crl:CD(SD) rats 
were purchased from Charles River Japan (Kanagawa, Japan). Adult male F344/N rats were 
purchased from Clea Japan (Tokyo, Japan). Animals were housed in a temperature- (23 ± 2°C) and 
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humidity- (55 ± 10%) controlled room with a 12h:12h light:dark cycle. All animals had free access to 
food and water. All animal experiments were approved by the Takeda Experimental Animal Care and 
Use Committee. 
 
Gonadotropin release assay in vivo 
Kp-54 or saline alone was injected s.c. into 25-day-old female Wistar rats (weighing 66 g on average) 
or 11-week-old male Wistar rats (weighing 350 g on average) at 0900–1000 h. The dose of Kp-54 was 
6.7 nmol/0.2ml saline for immature female rats or 35 nmol/0.2 ml saline for adult male rats. In an 
eCG-primed model, eCG (10 IU/0.2 ml saline) was pre-injected s.c. into immature female rats at 
0900–1000 h on day 23 (weighing 54 g on average). The rats were decapitated at 0, 1, 2, or 4 h after 
the injection and their trunk blood was collected into plastic tubes containing 1,000 U/ml aprotinin 
and 0.1 g/ml disodium-ethylenediaminetetraacetic acid. In Cetrorelix-treatment studies, Kp-54 (35 
nmol/0.2 ml saline) or saline alone (0.2 ml) was injected s.c. into 10-week-old male Wistar rats 
(weighing 410 g on average) that had been pretreated s.c. with either Cetrorelix (200 nmol/0.2 ml 
saline) or saline (0.2 ml) 30 min before the administration of Kp-54. The animals were decapitated 
and their trunk blood was collected 90 min after Kp-54 administration. In Cetrorelix-treatment studies 
in immature female rats, Kp-54 (3 nmol/0.2 ml saline) or saline alone (0.2 ml) was injected s.c. into 
25-day-old female Wistar rats, which had been administered with eCG 2 days before, that had been 
pretreated s.c. with either Cetrorelix (30 nmol/0.2 ml saline) or saline (0.2 ml) 30 min before the 
administration of Kp-54. The animals were decapitated and their trunk blood was collected 90 min 
after Kp-54 administration. All blood samples were prepared into plasma by centrifugation at 1,800 x 
g for 25 min at 4 °C, and subjected to radioimmunoassay (RIA). 
 
Ovulation Assay in Immature Rats 
Female Wistar rats at 23 days of age (weighing 54 g on average) were pretreated with eCG (10 IU/0.2 
ml saline, s.c.) at 0900–1000 h to induce follicular maturation. After 47–48 h (on day 25), the rats 
were treated with hCG (10 IU/0.2 ml saline, s.c.), Kp-54 (6.7 nmol/0.2 ml saline), or saline alone (0.2 
ml). After another 24 h (on day26), the rats were decapitated and their oviducts and uteri were 
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collected to count the number of oocytes with the aid of a stereomicroscope. The trunk blood was 
prepared into plasma to determine the plasma E2 and progesterone (P4) levels by RIA.  
 
Primary Culture of Rat Anterior Pituitary Cells 
The rat anterior pituitary cells were prepared as described previously (Matsumoto et al., 1990). Briefly, 
anterior pituitaries from male (7-week-old) or female (9-week-old) Wistar rats were dispersed by 
incubation with 0.4% collagenase A and 10 μg/ml DNase I and further incubation with 0.25% 
pancreatin. After large tissue debris were removed by filtering through 100 μm nylon mesh, dispersed 
cells were washed three times with DMEM containing 10% FCS, 20 mM HEPES, 50 U/ml penicillin 
and 50 μg/ml streptomycin, and cultured at 5 x 105 cells/well in 24-well plates for 3 days. Cells were 
then washed twice with 0.2% BSA-DMEM, pre-incubated in 0.2% BSA-DMEM at 37 °C for 30 min, 
and incubated with GnRH or Kp-54 in fresh 0.2% BSA-DMEM at 37 °C for 3 h. The FSH and LH 
levels in the conditioned media were determined using RIA. For testing the effect of E2, the cells 
were incubated in phenol red free DMEM-10% charcoal/dextran treated FCS with or without 10 nM 
E2. 
 
In vitro Ca
++
 Mobilization Assay 
Agonistic activities of TAK-448 and TAK-683 were evaluated as described previously (Ohtaki et al., 
2001; Terao et al., 2004; Asami et al., 2013). Briefly, rat KISS1R-expressing Chinese hamster ovary 
(CHO) cells were stimulated with various concentrations of the peptides, and intracellular Ca
++
 
mobilization was monitored by means of Ca
++
 indicator Fluo-3AM in FLIPR system (Molecular 
Devices, Sunnyvale, CA). The EC50 values and 95% confidence intervals (CI) (n = 3) were calculated 
by logistic regression analysis using the SAS system version 8.2 (SAS institute Inc, Cary, NC). In this 
assay system I also evaluated Kp-10 as internal control; the EC50 and 95% CI were 310 (274–351) 
pM in a representative experiment. 
  
In vitro Receptor Binding Assay 
Receptor binding affinity of TAK-448 and TAK-683 were evaluated by competitive receptor binding 
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assay using the membrane fraction of rat KISS1R-expressing CHO cells and 125I-labeled Kp-15 
(corresponding to N-terminal 15-aa residues of human Kp-54, originally called as metastin (40-54)) 
(Ohtaki et al., 2001). The IC50 values and 95% CI (n = 6) were calculated by logistic regression 
analysis using the SAS system. Kp-10 was also evaluated as internal control; the IC50 and 95% CI 
values were 130 (130–140) pM in a representative experiment. 
 
Seven-Day Repeat Dosing of TAK-448 in Male Rats 
Male SD rats (10 weeks of age, body weight range 372-460 g) were randomly assigned and 
subcutaneously injected once a day with either vehicle (5% glucose solution; Otsuka Pharmaceutical 
Laboratory, Tokushima, Japan) or TAK-448 (0.008, 0.08, 0.8, or 8 μmol/ml/kg) for consecutive 7 days 
(n = 4). Blood samples (0.4 ml) were obtained from tail vein at 0h (just before dosing) and 4h (4 h 
after dosing) on days 1, 4 and 7. Blood samples were immediately mixed with aprotinin solution 
containing 10% w/v of EDTA-2Na, and centrifuged to obtain plasma samples, and then stored below 
–30°C (for plasma hormone levels) or –80°C (for plasma drug concentrations) until measurement. On 
day 8 the prostate, the seminal vesicles, and the testes were removed and weighed. 
 
Seven-Day Repeat Dosing of TAK-683 in Male Rats 
Male SD rats (8 weeks of age, body weight range 284-308 g) were randomly assigned and 
subcutaneously injected once a day with either vehicle (5% glucose solution) or TAK-683 (0.008, 0.08, 
0.8, or 8 μmol/ml/kg) for consecutive 7 days (n = 4). The remaining procedure was identical as 
described above. 
 
Four-Week Continuous Administration of KISS1-305 or TAK-448 in Male Rats 
KISS1-305 (0.2-4 nmol/h), TAK-448 (100 pmol/h), leuprolide (0.3-2 nmol/h) were administered to 
male SD rats (9 weeks of age). Mini-pumps were implanted subcutaneously (s.c.) and replaced weekly 
as needed. Rats had a bilateral orchiectomy (ORX) performed on the day of dose initiation to compare 
the effect of ORX to effects produced by either kisspeptin analogues or leuprolide on plasma T and 
genital organ weights. Blood samples were obtained via tail vein, mixed with Trasylol solution 
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containing 10% (w/v) of EDTA-2Na, and centrifuged to obtain plasma samples for determination of 
plasma hormone levels. In studies to assess the impact of leuprolide or KISS1-305 on reproductive 
organ weights, the weights of the prostate, seminal vesicles, and testes were recorded at the end of the 
study immediately following animal sacrifice and normalized to body weight (% body weight). 
 
Four-Week Continuous Administration of TAK-448 or TAK-683 in Male Rats 
Two separate experiments were conducted. In the first experiment, male SD rats (9 weeks of age, 
body weight range = 318-368 g) were assigned to vehicle control, bilateral orchiectomy (ORX), 
TAK-448 or TAK-683 (10, 30, or 100 pmol/h), or leuprolide (30, 100, or 300 pmol/h) based on the 
body weight (n = 10). In the second experiment, male rats (9 weeks of age, body weight range = 
302-350 g) were assigned to vehicle, ORX, or TAK-448 (0.85, 3, or 10 pmol/h) based on the body 
weight (n = 9-10) to evaluate the effect of TAK-448 at lower doses. In both experiments, an osmotic 
ALZET minipump containing vehicle (50% DMSO; mixture of 1 volume of DMSO and 1 volume of 
distilled water) or compounds was implanted subcutaneously, and blood samples were collected 
before dosing (experimental day 0), 1, 2, 3 days after the initiation of dosing, and every 7 days after 
day 7. For ORX animals, I performed bilateral orchiectomy under anesthesia by isoflurane after blood 
collection on day 0. Plasma samples were prepared and stored as described above. On day 28, weights 
of the prostate, seminal vesicles, and testes were recorded and expressed as relative weight compared 
to each animal’s body weight (percent body weight). In other experiments, I verified the 
concentrations and the stability of the dosing formulations of TAK-448, TAK-683, or leuprolide by 
liquid chromatography. Based on the average initial body weight (Tables 3-2, 3-3), these doses can be 
approximately converted to nmol/kg/day with the conversion factor of 0.07 regardless of the 
compounds used (eg. 100 pmol/h is approximately equivalent to 7 nmol/kg/day). 
 
Twelve-Week Continuous Administration of TAK-683 in Male Rats 
Male rats (9 weeks of age, body weight range 313 - 340 g) were assigned to vehicle, ORX, TAK-683 
(30, 100, or 300 pmol/h), or leuprolide (100, 300, or 1000 pmol/h) based on the body weight (n = 4-5). 
Blood samples were collected before dosing (experimental day 0), 1, 2, 3 days after the initiation of 
   15  
 
dosing, and every 7 days after day 7, and plasma samples were prepared and stored as described 
above. On day 84, weights of the prostate, seminal vesicles, and testes were recorded and expressed as 
percent body weight. Doses can be converted to "nmol/kg/day" by the conversion factor of 0.07. 
 
Antitumor Study in JDCaP Prostate Tumor Model 
The JDCaP tumor xenograft was maintained as described previously (Kimura et al., 2009). A small 
piece of JDCaP tumor was transplanted under the renal capsule of male F344/N nude rats. Forty-two 
days following tumor transplantation, animals were stratified according to baseline serum PSA levels. 
Groups of 7 animals were subsequently treated with TAK-683, leuprolide, ORX, or vehicle only. 
TAK-683 (1.4 or 7 nmol/kg/day) and leuprolide (1.4 or 7 nmol/kg/day) were administered as 
continuous s.c. infusions using osmotic ALZET minipumps. Serum PSA level was determined before 
treatments over time for 240 days after the initiation of treatment by using a commercially available 
EIA kit (Markit-M PA, Dainippon Sumitomo Pharma, Osaka, Japan), and the lower detection limit 
was 0.5 ng/ml. Values below the detection limit were expressed as 0.5 ng/ml. 
 
Assessment of LH Release after Chronic Administration of KISS1-305 
Male rats were administered either vehicle, KISS1-305 (2 nmol/h), or leuprolide (2 nmol/h) for 6 days, 
followed by a single s.c. administration of 100 nmol/kg of KISS1-305 or leuprolide. Blood samples 
were collected through a jugular vein catheter that had been implanted on day 5, and on the next day 
blood samples were collected before the single s.c. dose, and at 5, 15, 30, 60, and 120 min after dosing 
to determine plasma LH levels using the commercially available RIA kit. 
To explore the responsiveness of GnRH neurons to the GnRH secretagogue 
N-methyl-D-aspartate (NMDA, Sigma-Aldrich), male rats were treated with either vehicle or 
KISS1-305 (4 nmol/h) for 6 days as described above, followed by a single s.c. administration of NMDA 
(30 mg/kg) or vehicle. Blood samples were collected via tail artery before and 15 min after the NMDA 
dose to determine plasma LH levels. This blood sampling point (15 min) was chosen based on results 
from a pilot experiment. Briefly, to examine the time course of LH elevation after single s.c. 
administration of NMDA in male rats, NMDA (30 mg/kg) or saline (vehicle) was administered s.c. in 
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male Crl:CD(SD) rats (9 weeks of age, n = 3). Blood samples were collected before and 15, 30, and 60 
minutes after the NMDA dosing to determine plasma LH levels by RIA. 
 
Brain Fixation and Immunohistochemistry (IHC) 
The brain fixation and immunohistochemical analysis of GnRH and c-Fos were performed as 
described previously. Briefly, following euthanasia, the brain was fixed by transcardial perfusion with 
Mildform 10N (Wako Pure Chemical Industries, Osaka, Japan). The brain was dissected out, and 
coronal sections (30-50 μm) were cut on a cryostat and mounted onto glass slides. Sections were 
incubated overnight with a polyclonal goat antibody raised against c-Fos (1:50, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and a polyclonal rabbit antiserum raised against rat GnRH 
(1:250, Sanbio, Uden, The Netherlands), and then with Cy5-conjugated donkey anti-goat IgG and 
fluorescein-conjugated donkey anti-rabbit IgG (1:50, Jackson Immuno Research Laboratories, West 
Grove, PA, USA) for 3 h at room temperature. Cellular nuclei were counterstained using 
4',6-diamidino-2-phenylindole dihydrochloride (DAPI). The sections were examined with the aid of a 
TCS SP2 confocal microscope (Leica, Rockleigh, NJ, USA). The number of GnRH-immunoreactive 
(ir) neurons in which the nucleus was stained with DAPI was counted. The hypothalamus was divided 
into four regions, the OVLT-aPOA, the POA, the SON-PVN, and the mediobasal hypothalamus 
(MBH) (positioned at 0–150, 150–900, 900–1600, and 1,600–3,000 μm caudal from the OVLT, 
respectively). These subdivisions include the organum vasculosum of the lamina terminalis (OVLT) 
and the anterior preoptic area (aPOA), the preoptic area (POA), the supraoptic nucleus (SON) and the 
paraventricular nucleus (PVN), and the caudal part of the forebrain, respectively. 
 
Effect of NMDA on c-Fos-ir Expression 
Male Crl:CD(SD) rats received either vehicle or KISS1-305 for 6 days as described in Methods, 
followed by a single s.c. administration of NMDA (30 mg/kg) or vehicle. Ninety minutes after the 
NMDA dose, the brain was fixed as described in Methods for immunohistochemical c-Fos evaluation. 
Frozen serial coronal cryomicrotome sections (50 μm) of the brain were made to detect c-Fos-ir. Using 
a free floating technique, sections were washed with PBS and immersed sequentially in the following 
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solutions: 1) 1% sodium metaperiodate in PBS for 10 min, 2); 10% normal donkey serum (Jackson 
Immuno Reserch, #017-000-121) and 0.3% Triton X-100 in PBS for 1 h; 3) goat anti-c-Fos polyclonal 
antibody (1:100; Santa Cruz Biotechnology, #SC52G) overnight; 4) biotinylated anti-Goat IgG (H+L) 
(1:300; Vector Laboratories [Burlingame, CA], #BA-5000) for 90 min; 5) avidin-biotinylated HRP 
complex (ABC Elite; Vector Laboratories, #PK-6100) for 30 min; and 6) ImmPACT DAB solution 
(Vector Laboratories, #SK-4105) for 3-4min. The sections were mounted, dehydrated and examined by 
light microscopy. 
 
Gene mRNA and Protein Expression Analysis after Chronic Administration of KISS1-305 
The hypothalamus was dissected from the brain of euthanized animals that had received chronic 
KISS1-305 for 3 weeks, as described previously by Kumano et al. (Kumano et al., 2003). For protein 
analysis, the hypothalamic samples were weighed immediately after tissue collection, followed by 
boiling for 5 min in 1 mL of DW, and then chilled on ice until sample homogenization. After 
homogenization in DW, 1/16 volume of glacial acetic acid (Wako Pure Chemical Industries) was added 
to the homogenate, which was gently rotated at 4°C for 1hr, followed by centrifugation for 5 min at 
15,000 rpm (MX305, Tomy, Tokyo, Japan). The supernatant from the hypothalamic homogenate was 
then applied to a SepPak C18 column (Waters, Milford, MA), washed once with 1M acetic acid in DW, 
and eluted with 60% CH3CN containing 0.1% trifluoroacetic acid in DW. The elution was then 
lyophilized and stored at -30°C until GnRH determination. Hypothalamic GnRH contents were 
determined by RIA (as described below), normalized to the tissue weight, and expressed as relative 
values (arbitrary units) versus GnRH detected in vehicle control treated animals. For mRNA analysis, 
hypothalamic total RNA was purified using RNeasy Mini Kit (Qiagen, Valencia, CA), followed by first 
strand cDNA synthesis using SuperScript III reverse transcriptase and oligo(dT)20 primers (Invitrogen). 
Expression of rat mRNA for Kiss1, Kiss1r, Gnrh and β-actin were determined by quantitative 
polymerase chain reaction (qPCR, 7900HT Fast Real-Time PCR System, Applied Biosystems, Foster, 
CA). Gene-specific probes and primers used for Kiss1, Kiss1r, and β-actin have been described 
previously (Kinoshita et al., 2005); the following primers and probe were used for Gnrh; forward: 
5’-GCAGAACCCCAGAACTTCGA-3’, reverse: 5’-TGCCCAGCTTCCTCTTCAAT-3’, and probe: 
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5’-(FAM)-TCTGCGAGGAGCTCTGGAACGTCTG-(TAMRA)-3’. mRNA expression levels were 
normalized to those of β-actin, and then expressed as relative values (arbitrary units) versus vehicle 
control-treated animals. 
 
Gene mRNA and Protein Expression Analysis after ORX or Chronic Administration of TAK-448 
or lLuprolide  
After 1 (n = 5) or 4 weeks (n = 10) post-ORX or treatment with TAK-448 (100 pmol/h), or leuprolide 
(300 pmol/h), the brain, pituitary, and blood samples were collected from euthanized animals to 
determine hypothalamic GnRH peptide contents by RIA, hypothalamic Gnrh and pituitary Fshb and 
Lhb mRNA expressions by qPCR, pituitary FSH and LH contents, and plasma FSH, LH, and T levels by 
RIA. For protein analysis, weights of the hypothalamus and pituitary glands were recorded immediately 
after tissue collection and the hypothalamic GnRH contents were determined by RIA as described 
above. The pituitary was homogenized in 0.3 mL of phosphate buffered saline containing 1 complete 
protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany), followed by 
centrifugation for 5 min at 15,000 rpm. The supernatants were stored at -80°C until determination of 
FSH and LH contents by RIA (see below). The GnRH, FSH, and LH contents were expressed as relative 
values (%) versus vehicle control. For qPCR analysis, total RNA from the hypothalamus or pituitary 
was purified as described above, and mRNA expressions were determined by qPCR using TaqMan
®
 
Gene Expression Assays (Applied Biosystems), for β-actin (Actb: Rn00667869_m1), for Gnrh (Gnrh1: 
Rn00562754_m1), for Fshb (Rn01484594_m1), and for Lhb (Rn00563443_g1). Expression levels of 
mRNA were analyzed by the ΔCt method using β-actin as the internal control, and expressed as relative 
expression levels (arbitrary units) versus vehicle controls. 
 
Radioimmunoassay (RIA) 
Plasma levels of FSH and LH were determined using rat FSH (rFSH-RP-2 for reference peptide) and 
LH (rLH-RP-3 for reference peptide) RIA kits, which were used according to the instruction from 
NIDDK. The detection limits for FSH and LH were 0.8 and 0.08 ng/mL, respectively, in 100μL of 
reaction volume. Intra-assay (n = 9) and inter-assay (n = 3) coefficients were 3.3% and 0.63% at 21 
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ng/mL for FSH and 4.2% and 1.4% at 5.7 ng/mL for LH, respectively. In some experiments, I also used 
commercially available rat FSH and LH RIA (radioimmunoassay) kits, respectively (Amersham 
Biosciences, NJ, USA). The detection limits of these RIA kits were 1.6 ng/ml (FSH) and 0.8 ng/ml 
(LH), and the values under the detection limits were determined as 0 ng/ml. My pilot experiment on 
the cross-reactivity of these commercially available RIA kits to 1 IU/ml of eCG revealed that it was 
equivalent to 5.4 ng/ml of rat LH, while it was undetectable using rat FSH RIA kit. Plasma T, E2 and 
progesterone (P4) were determined using a DPC total testosterone kit, DPC estradiol kit and a DPC 
progesterone kit, respectively (Diagnostic Products, CA, USA). The detection limits of these RIA kits 
were 0.04 ng/mL (T), 8 pg/ml (E2) and 0.02 ng/ml (P4). GnRH levels were determined using a 
commercially available RIA kit with a detection limit of 0.01 ng/mL. Values less than the lower limit of 
detection were set equal to the detection limit. All procedures were performed according to the 
manufacturer’s instructions.  
 
Determination of Plasma Drug Concentrations 
Plasma TAK-448 and TAK-683 concentrations were determined either by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) or EIA (Yoshida et al., 2012). For 
LC-MS/MS, the plasma samples were deproteinized by adding methanol, formic acid and acetone, 
followed by centrifugation to obtain supernatant. The supernatant was then evaporated to dryness 
under a stream of nitrogen at 50°C, and the residue was reconstituted in ultra pure water containing 
1/500 volume of formic acid and centrifuged to obtain supernatant. The supernatant was applied to a 
solid phase cartridge (OASIS HLB, Waters, Milford, MA) and then eluted by methanol, followed by 
evaporation under a stream of nitrogen at 50°C. The residue was reconstituted in ultra pure water 
containing 0.2% formic acid/methanol (4:1, v/v), then filtered (0.22 μm; Ultra-free MC, Millipore, 
Billerica, MA), and finally injected into the LC-MS/MS system. Plasma leuprolide concentrations 
were determined by RIA as described previously (Yamazaki & Okada, 1980). The detection limit for 
each assay was 50 pg/ml for TAK-683 by LC-MS/MS, 5 pg/ml for TAK-683 by EIA, 3 pg/ml for 
TAK-448 by EIA, and 50 pg/ml for leuprolide by RIA. 
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Statistics 
Statistical significance was analyzed using the SAS system version 8.2 (SAS institute Inc, Cary, NC). 
Differences were considered to be significant when P values were ≤0.05 (two-tailed test) or ≤0.025 
(one-tailed test). The homogeneity of variance for multiple groups was analyzed by the F test (two 
groups) or Bartlett’s test (multiple groups). If the results were not significant, the data were analyzed by 
parametric statistics. If the results were significant, the data were analyzed by nonparametric statistics. 
Specific statistical method used for each data will be described in each Figure or Table legends. 
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Chapter 1: Peripheral Administration of Kisspeptin Induces 
Marked Gonadotropin Release and Ovulation in the Rat 
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Results 
In this Chapter, I will describe the functional analysis of kisspeptin in the rat by focusing on the effect 
of subcutaneous administration of Kp-54 or a kisspeptin agonist analogue (KISS1-305) on 
reproductive functions. 
 
Ovulation-inducing Activity in Prepubertal Intact Female Rats 
Kp-54 administration to the eCG-primed rats promoted the ovulation of a large population of oocytes, 
comparable to that attained by hCG administration (Table 2). On day 25, untreated rats showed low 
E2 and low P4 levels (8.9 pg/ml and 1.8 ng/ml on average, respectively) whereas the eCG-treated rats 
showed increased E2 and low P4 levels (164.4 pg/ml and 2.2 ng/ml on average, respectively). The 
increase in E2 levels is a sign of the maturation of follicles. On day 26 (24 h after the injection of 
Kp-54 or hCG), the E2 levels in the Kp-54- and hCG-treated rats returned to similarly lower levels, 
while those in saline-treated rats remained high (Table 2). In contrast, the P4 levels in the Kp-54- and 
hCG-treated rats were elevated, but there was some difference in the increase of P4 levels between 
these two groups (Table 2). 
 
Table 2 Number of ovulated oocytes, and plasma E2 and P4 levels. 
 
eCG-primed 25-day-old female Wistar rats were treated with Saline, kisspeptin, or hCG, and sacrificed 
on 26 days.  Data shown are mean ± SEM. Significant differences are observed between the different 
letters (P < 0.01, Tukey’s test, n = 5).          
 
 
I also tested another kisspeptin agonist, KISS1-305, and demonstrated that the pituitary is 
indispensable for ovulation-inducing activity by kisspeptin agonist (Data not shown). 
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Gonadotropin-releasing Activity in eCG-primed Immature Female Rats 
I next investigated the effect of Kp-54 on plasma gonadotropin levels in eCG-primed 25-day-old rats 
having maturated follicles. Though basal FSH levels (saline-treated group) in the eCG-primed rats 
showed slight temporal changes (statistically significant), Kp-54 administration significantly elevated 
plasma FSH and LH levels compared to each zero-time level and also compared to saline-treated 
group at each time point (Fig. 2). The result affirms that the follicles in Kp-54-treated rats received 
surge-like LH stimulation; the preovulatory LH surge is known to decrease the levels of E2 and to 
enhance the synthesis of P4 in follicles (Fortune & Hansel, 1985). The higher P4 levels in 
hCG-treated rats may be due to the excessive stimulation of luteal cells because of its higher stability 
compared to LH (European Recombinant LH Study Group, 2001) 
 
 
 Kp-54 administration elevates plasma gonadotropin levels in eCG-primed prepubertal Fig. 2
female rats. 
Plasma FSH (A) and LH (B) levels in eCG-treated 25-day-old rats after saline (open) or Kp-54 
(shaded) administration (n = 5).  Data shown are mean + SEM.  The letters a, b, and c indicate P < 
0.05, 0.01, and 0.001 versus time 0 control of each group by Dunnett’s test.  The symbols *, **, and 
*** indicate P < 0.05, 0.01, and 0.001 versus saline-treated control at each time by Student’s t-test. 
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 The effect of GnRH or Kp-54 on gonadotropin release from female rat anterior Fig. 3
pituitary cells in vitro.  
FSH (A,C) and LH (B,D) levels in the conditioned medium of female pituitary cells cultured in the 
presence (A,B) or absence (C,D) of 10nM E2 in phenol red-free DMEM are shown versus GnRH 
concentrations. Open bars, 0M; dotted bars, 10
-10
 M; hatched bars, 10
-8
 M; and closed bars, 10
-6
 M of 
Kp-54. Data shown are mean + SEM. 
 
Gonadotropin-releasing Assay in Primary Culture of Rat Anterior Pituitary Cells 
Kp-54 did not induce gonadotropin release in any dose, while GnRH successfully induced LH release 
in a dose-dependent manner from the primary cultured male or female pituitary cells (Data not shown). 
Because it has been shown that phenol red had estrogenic effect on the rat pituitary cells (Dumesic et 
al., 1989), I next cultured female rat anterior pituitary cells in the presence or absence of 10 nM E2 in 
phenol red-free medium, and the cells were incubated with GnRH, Kp-54, or both (Fig. 3). Kp-54 did 
not induce gonadotropin release nor affect the GnRH-induced gonadotropin release. 
 
Gonadotopin-releasing Activity in Prepubertal Female Rats and Adult Male Rats 
Subcutaneous administration of 6.7 nmol/body (ca. 100 nmol/kg) of Kp-54 markedly elevated plasma 
FSH and LH levels compared to each zero-time level and also compared to saline-treated group at 
   25  
 
each time point in 25-day-old female rats without eCG treatment (Fig. 4). The maximal increase was 
found 2 h after administration. Saline-treatment did not induce any significant changes in these 
hormone levels.  
 
 
 
 Kp-54 administration elevates plasma gonadotropin levels in prepubertal female rats Fig. 4
without eCG treatment. 
Plasma FSH (A) and LH (B) levels in 25-day-old rats after saline (open) or Kp-54 (shaded) 
administration (n = 5).  Data shown are mean + SEM.  The letters a, b, and c indicate P < 0.05, 0.01, 
and 0.001 versus time 0 control of each group by Dunnett’s test.  The symbols *, **, and *** 
indicate P < 0.05, 0.01, and 0.001 vs. saline-treated control at each time by Student’s t-test. 
 
Next I investigated the gonadotropin releasing effect in adult male rats. Subcutaneous 
administration of Kp-54 to adult male Wistar rats markedly elevated the plasma levels of FSH and LH, 
with the maximum increase occurring 2 h after administration (Fig. 5). The pre-treatment with 
Cetrorelix, a GnRH antagonist, suppressed both FSH and LH elevations in response to Kp-54 (Fig. 5).  
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 The effect of kisspeptin on gonadotropin release in adult male Wistar rats Fig. 5
Data shown are mean + SEM. Plasma FSH (A) and LH (B) levels in 10-week-old rats after treatment 
with kisspeptin (closed square) or saline (open square) (n = 5). The letters b and c indicate  < 0.01 
and 0.001 versus time 0 control of each group by Dunnett’s test, respectively. The symbols ** and *** 
indicate P < 0.01 and 0.001 versus saline-treated control at each time by Student’s t test, respectively. 
Plasma FSH (C) and LH (D) levels in 10-week-old rats 90 min after treatment with either Kp-54 (+K) 
or saline (+S), following pretreatment with Cetrorelix (C+) or saline (S+) (n = 5). ***P < 0:001 
versus the other three groups by Tukey’s test. 
 
 
Induction of c-Fos Immunoreactivity in GnRH Neurons 
Kp-54-treated rats (n = 2) exhibited a large population of c-Fos and GnRH-double-immunoreactive 
(ir) neurons in the hypothalamus, whereas saline-treated rats (n = 2) exhibited no c-Fos-ir GnRH 
neurons (Fig. 6). The proportion of c-Fos-ir GnRH neurons in the total population of GnRH neurons 
was highest in the OVLT-aPOA, moderate in the POA and in the MBH, and low in the SON-PVN 
(Table 3). These results suggest that GnRH neurons in the hypothalamus are activated after Kp-54 s.c. 
administration. 
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 Double-labeling immunohistochemistry. Fig. 6
c-Fos (red) and GnRH (green) immunoreactivity in the aPOA at the level of the OVLT in 
saline-treated (A,B) or kisspeptin-treated (C,D) male Wistar rats. Blue signals indicate DAPI-stained 
nuclei. (B,D) Higher-magnification images of the fields shown in (A,C), respectively. Arrows and 
arrowheads indicate c-Fos-negative and positive GnRH neuronal bodies, respectively. 3V, the third 
ventricle. Bars; 100 μm in (A,C), and 40μm in (B,D). 
 
 
Table 3 The proportion of c-Fos-immunoreactive GnRH neurons in kisspeptin-treated adult 
male rats.   
 
Values are the total from two rats.  The definitions of subdivisions are described in material and 
method. 
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Chapter 2: Pharmacologic Profiles of Investigational 
Kisspeptin/Metastin Analogues, TAK-448 and TAK-683, in Adult 
Male Rats in Comparison to the GnRH Analogue Leuprolide 
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Results  
In this Chapter, I will describe the pharmacological profiles of kisspeptin agonist analogues especially 
focusing on potential application of kisspeptin agonist analogues for hormone-related disease 
treatment. 
 
In vitro Properties of TAK-448 and TAK-683 
The in vitro properties of KISS1-305 has been previously published (Asami et al., 2013). In vitro, 
TAK-448 and TAK-683 were both found to be potent and full KISS1R agonists; IC50 values (95% 
CI) from receptor binding assays were 460 (420 – 500) pM for TAK-448 and 170 (150 – 180) pM for 
TAK-683 (n = 6), and EC50 values (95% CI) from Ca
++
 mobilization assays were 632 (558 – 716) pM 
for TAK-448 and 180 (159 – 203) pM for TAK-683 (n = 3). TAK-683 showed approximately three 
times more potent receptor binding and agonistic activity compared to TAK-448.  
 
Four-Week Continuous Administration of KISS1-305 in Male Rats 
I studied the dose dependency and time course of T lowering produced by KISS1-305. Chronic 
administration of KISS1-305 (0.2, 0.5, 1 nmol/h) transiently elevated plasma T levels (Fig. 7A). 
KISS1-305 (1 nmol/h) reduced plasma T levels to the lower limit of detection (0.04 ng/mL) at day 3 and 
day 28 (Fig. 7B), but the efficacy was not sustained. I also studied the effect of KISS-305 at higher 
doses (1, 2, or 4 nmol/h) in comparison to leuprolide. Consistent with the above findings, chronic 
administration of KISS1-305 (1, 2, or 4 nmol/h) resulted in a temporal rise in plasma T levels and 
reduction in T levels to the lower limit of detection by day 3 at every dose evaluated (Fig. 7C). T levels 
at day 28 were also undetectable and significantly lower than vehicle controls (Fig. 7D). In groups 
receiving 2 and 4 nmol/h, plasma T levels were depleted for the entire 4-week administration period 
(Fig. 7C), suggesting that 2 nmol/h of KISS1-305 could be considered the minimum effective dose. In 
contrast, while chronic leuprolide administration (1 nmol/h) did result in T flare of approximately the 
same magnitude as that observed following KISS1-305 dosing, chronic leuprolide dosing did not result 
in maximal T lowering until 2 weeks following the initiation of chronic dosing (Fig. 7A). Dose 
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dependency of leuprolide was also examined. The results revealed that the T-lowering effect of 
leuprolide appeared to plateau at a chronic dose ≥0.3 nmol/h (data not shown). These results suggest 
that T lowering with KISS1-305 is more rapid and of greater magnitude than that produced by 
leuprolide. Prostate, seminal vesicles, or testes tissue weights (a direct reflection of circulating T or 
gonadotropins) on day 28 were significantly reduced both in KISS1-305- and leuprolide-treated 
animals but the administration of KISS1-305 resulted in a greater reduction in genital organ weight than 
leuprolide under these conditions (Fig. 7E). 
 
 Effect of chronic s.c. administration of KISS1-305 or leuprolide in male rats Fig. 7
(A) KISS1-305 was chronically administered to male rats, and mean plasma T levels at day 0 (pre), 4, 
8, 24, 36, 48, 60, 72 h, and 7, 10, 14, 17, 21, and 28 days after treatment are shown. (B) Plasma T 
levels on day 28. (C) KISS1-305 or leuprolide were chronically administered to male rats, and mean 
plasma T levels at day 0 (pre), 8 h, and 1, 2, 3, 7, 14, 21, and 28 days after treatment are shown. (D) 
Plasma T levels on day 28. (E) Relative weights of the testes, prostate, and seminal vesicles (S.V.) on 
day 28. Data shown in B, D, and E are mean + SD (n = 5). * and ** indicate P < 0.025 and < 0.01 
versus vehicle by one-tailed Shirley-Williams’ test and Aspin-Welch t-test, respectively.  
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Seven-Day, Once-Daily Repeat Dosing of TAK-448 or TAK-683. 
The first dosing of TAK-448 induced substantial elevation in plasma LH and testosterone levels at 4h 
(Fig. 8A-B). The baseline plasma LH and testosterone levels either or both on days 4 and 7 (i.e. at 0h 
on each experimental day) were decreased below the vehicle control levels; especially the latter was 
as low as below the detection limit (0.04 ng/ml). Responses to a new TAK-448 daily injection were 
not apparent on days 4 and 7 in terms of LH release. Testosterone levels were slightly increased in 
response to a new daily injection on days 4 and 7 especially at doses of 0.08 μmol/kg and less; while 
the testosterone levels after a new daily injection were still significantly lower compared to the 
vehicle control at doses of 8 μmol/kg (Day 4) and ≥0.08 μmol/kg (Day 7). The weights of the prostate, 
the seminal vesicles, and the testes on day 8 were significantly reduced compared to vehicle-treated 
group (Fig. 8C). Similar results were obtained with TAK-683 (Fig. 9), and the testosterone levels on 
day 7 at 4 h after a new TAK-683 administration were significantly lower than vehicle control at doses 
of 0.8 μmol/kg and above (Fig. 9B). It appears that TAK-448 produced more profound suppression of 
the baseline LH and testosterone levels observed at 0h on days 4 and 7 and the weights of testis, the 
differences between TAK-448 and TAK-683 were not apparent in terms of the weights of prostate and 
seminal vesicles (Fig. 9C). 
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 Effect of repetitive administration of TAK-448 in male rats. Fig. 8
Plasma LH (A) and testosterone (B) levels at 0 and 4 h on experimental days 1, 4, and 7, showing 
suppressions of LH and testosterone after repeated dosing. These hormone profiles were first analyzed 
by repeated measures 2-way analysis of variance (ANOVA), and the main effect of dose (LH), main 
effect of time (LH and testosterone) and interaction effect (LH and testosterone) were considered to be 
significant (P < 0.05). The data were then analyzed by two-tailed Willams' or Shirley-Williams test, 
and † indicates P < 0.05 versus vehicle control. (C) The weights of the prostate, the seminal vesicles 
and the testes on day 8 were reduced in a dose-dependent manner. Data shown are mean + S.D. (n = 
4).  * indicates P < 0.025 (one-tailed Williams' or Shirley-Williams test) versus vehicle control. 
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 Effect of repetitive administration of TAK-683 in male rats. Fig. 9
Plasma LH (A) and testosterone (B) levels at 0 and 4 h on experimental days 1, 4, and 7, showing 
suppressions of LH and testosterone after repeated dosing. These hormone profiles were first analyzed 
by repeated measures 2-way analysis of variance (ANOVA), and the main effect of dose, main effect 
of time and interaction effect were considered to be significant for both hormone profiles (P < 0.05). 
The data were then analyzed by two-tailed Willams' or Shirley-Williams test, and † indicates P < 0.05 
versus vehicle control. (C) The weights of the prostate, the seminal vesicles and the testes on day 8 
were reduced in a dose-dependent manner. Data shown are mean + S.D. (n = 4).  * indicates P < 
0.025 (one-tailed Williams' or Shirley-Williams test) versus vehicle control. 
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Four-Week and 12-Week Continuous Administration of Kisspeptin Analogues. 
I then evaluated the effect of continuous s.c. administration of TAK-448 (0.7, 2.1, or 7 nmol/kg/day; 
doses are described in the converted doses as mentioned in the Materials and Methods), TAK-683 (0.7, 
2.1, or 7 nmol/kg/day), or leuprolide (2.1, 7, or 21 nmol/kg/day) in male rats, and the effects were 
compared to ORX. Plasma concentrations of all three peptides were dose-dependent, confirming 
appropriate and stable drug release during this study period (Table 4). Mean plasma concentrations 
during this 4-week dosing periods showed that at the same dose TAK-448 produced about 50% higher 
plasma drug concentrations than TAK-683, suggesting that TAK-448 had better pharmacokinetic 
profiles in this subcutaneous infusion setting (Table 4). 
 
 
Table 4 Plasma drug concentrations in subcutaneous infusion studies 
 
a: PK values from the infusion study shown in Fig. 11 
b: PK values from the infusion study shown in Fig. 10 
 
 
 Both TAK-448 and TAK-683 administration induced an increase in plasma testosterone 
levels only on day 1, followed by abrupt reduction of plasma testosterone levels by day 3. In this study, 
continuous administration of 0.7 nmol/kg/day of TAK-448 or 2.1 nmol/kg/day of TAK-683 was 
sufficient to maintain complete suppression of testosterone (below the detection limit; 0.04 ng/ml) for 
4 weeks (Fig. 10A-B). I defined the castrate level as “mean + 2 S.D. of the ORX group”, and found 
that TAK-448 (≥ 0.7 nmol/kg/day) and TAK-683 (≥ 2.1 nmol/kg/day ) reduced the weights of the 
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prostate or seminal vesicles to, or close to, the castrate level (Fig. 10C-E). In contrast, while 
continuous leuprolide administration resulted in testosterone flare of approximately the same 
magnitude as that observed following administration of TAK-448 or TAK-683, continuous leuprolide 
dosing took 2 weeks to induce maximal plasma testosterone reduction (Fig. 10A-B). Though 
leuprolide treatment significantly reduced the weights of the prostate, seminal vesicles, and testes, 
both TAK-448 and TAK-683 showed more pronounced reduction in weights of these organs (Fig. 
10C-E).  
 
 
 Effect of continuous administration of TAK-448, TAK-683, and leuprolide in male rats. Fig. 10
(A) Mean plasma testosterone levels at indicated time points. Plasma testosterone levels (B), relative 
weights of the prostate (C), the seminal vesicles (D), and the testes (E) on day 28. Data shown are 
mean + S.D. unless otherwise stated. The lower limit of quantification of testosterone was 0.04 ng/ml, 
and values below the limit were expressed as 0.04 ng/ml. Dashed lines in figures (C) and (D) indicate 
castrate levels (mean + 2 S.D. of ORX). As stated in the section 3.2, the doses can be converted to 
μg/kg/day with the conversion factor of 0.09. * indicates P < 0.025 (one-tailed Williams’ test; ORX) 
or P < 0.05 (Wilcoxon rank sum test; TAK-448, TAK-683, leuprolide) versus vehicle control. 
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At the end of the study little difference in body weights were observed between treatments 
(Table 5). 
Table 5 Body weights in the experiment shown in Fig. 10 
 
Since this first study could not clarify dose-dependent efficacy of TAK-448, I conducted 
another experiment with lower dose of TAK-448 (0.06, 0.21, and 0.7 nmol/kg/day) to estimate the 
minimum effective dose. Stability studies revealed that in the stock solution used for the lowest dose, 
the actual concentration of TAK-448 was 85% of the nominal concentration, probably due to 
absorption to the container. Therefore, the lowest administered dose of TAK-448 was calculated to be 
0.06 nmol/kg/day rather than the nominal value of 0.07 nmol/kg/day. The concentrations of TAK-448 
in the stock solutions used for the 0.21, and 0.7 nmol/kg/day doses were found to be accurate and 
stable. The results demonstrated that 0.7 nmol/kg/day of TAK-448 was sufficient to completely 
suppress plasma testosterone levels below the detection limit for 4 weeks with well-maintained 
plasma drug concentrations (Table 6 and Fig. 11A-B). All three dose levels reduced the weights of the 
prostate, seminal vesicles, and testes; at 0.7 nmol/kg/day the weights of the prostate and seminal 
vesicles were reduced to the castrate level (Fig. 11C-E). Little differences in body weights between 
treatments were observed at the end of the study (Table 6). 
Mean ± SD
Group
Vehicle 346 ± 11 459 ± 17
ORX 346 ± 7 445 ± 11
TAK-448 0.7 nmol/kg/day 345 ± 14 454 ± 30
TAK-448 2.1 nmol/kg/day 346 ± 13 443 ± 29
TAK-448 7 nmol/kg/day 345 ± 10 453 ± 18
TAK-683 0.7 nmol/kg/day 347 ± 8 458 ± 17
TAK-683 2.1 nmol/kg/day 346 ± 12 456 ± 25
TAK-683 7 nmol/kg/day 342 ± 10 447 ± 24
Leuprolide 2.1 nmol/kg/day 346 ± 11 448 ± 20
Leuprolide 7 nmol/kg/day 345 ± 9 451 ± 21
Leuprolide 21 nmol/kg/day 346 ± 12 448 ± 23
Day 0 Day 28
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 Effect of continuous administration of TAK-448 in male rats. Fig. 11
(A) Mean plasma testosterone levels at indicated time points. Plasma testosterone levels (B), relative 
weights of the prostate (C), the seminal vesicles (D), and the testes (E) on day 28. Data shown are 
mean + S.D. unless otherwise stated. The lower limit of quantification of testosterone was 0.04 ng/ml, 
and values below the limit were expressed as 0.04 ng/ml. Dashed lines in figures (C) and (D) indicate 
castrate levels. As stated in the section 3.2, the doses can be converted to μg/kg/day with the 
conversion factor of 0.09. * indicates P < 0.025 (one-tailed Williams’ test; ORX) or P < 0.05 
(Wilcoxon rank sum test; TAK-448) versus vehicle control. 
 
 
 
Table 6 Body weights in the experiment shown in Fig. 11 
 
  
Mean ± SD
Vehicle 330 ± 11 460 ± 40
ORX 326 ± 11 443 ± 35
TAK-448 0.06 nmol/kg/day 328 ± 12 459 ± 27
TAK-448 0.21 nmol/kg/day 330 ± 10 444 ± 14
TAK-448 0.7 nmol/kg/day 331 ± 9 434 ± 23
Day 0 Day 28
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I also evaluated the effect of continuous infusion of TAK-683 in male rats for 12 weeks (Fig. 
12), and confirmed the testosterone suppressive effect was maintained at least for 12 weeks in male 
rats. 
 
 
 Effect of continuous administration of TAK-683 for 12 weeks in male rats. Fig. 12
(A) Plasma drug concentrations at 4 and 12 weeks. (B) Mean plasma testosterone levels at indicated 
time points. Plasma testosterone levels at 4 (open bars) and 12 weeks (solid bars) (C), relative weights 
of the prostate (D), the seminal vesicles (E), and the testes (F) at 12 weeks. Data shown are mean + 
S.D. unless otherwise stated. The lower limit of quantification of testosterone was 0.04 ng/ml, and 
values below the limit were expressed as 0.04 ng/ml. Dashed lines in figures (D) and (E) indicate 
castrate levels. * indicates P < 0.025 (one-tailed Williams’ test; ORX) or P < 0.05 (Wilcoxon rank 
sum test; TAK-683) versus vehicle control. Note that differences in plasma testosterone levels were 
considered to be significant only when the values were significantly reduced at both 4 and 12 weeks. 
 
 
Antitumor Effect of TAK-683 in JDCaP Prostate Tumor Model. 
In male nude rats bearing JDCaP prostate tumor, I evaluated antitumor effect of TAK-683, as a 
representative of kisspeptin analogues, in comparison to leuprolide. Doses were 1.4 and 7 
nmol/kg/day for both compounds. Serum concentrations of PSA were reduced in rats treated with 
TAK-683, leuprolide, or ORX (Fig. 13), compared with rats treated with vehicle control. Leuprolide 
(1.4 or 7 nmol/kg/day) treatment resulted in elevated serum PSA levels on day 3, but neither treatment 
with TAK-683 nor ORX induced PSA elevation on day 3 (Fig. 13A). PSA concentrations were 
reduced to below the limit of detection (0.5 ng/ml) in all rats by day 7 (ORX), day 14 (TAK-683, 1.4 
and 7 nmol/kg/day), day 42 (leuprolide, 7 nmol/kg/day), or day 56 (leuprolide 1.4 nmol/kg/day) after 
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treatment initiation (Fig. 13B). At the doses studied, both ORX and TAK-683 induced a significantly 
more rapid reduction in serum PSA levels to below the limit of detection compared to leuprolide (P ≤ 
0.01, log-rank test). 
 
 
 Effect of continuous administration of TAK-683 on serum PSA levels in JDCaP Fig. 13
tumor-bearing rats. 
(A) Serum PSA levels over time with the magnified y-axis to clearly show PSA changes in each 
treated group. The inset shows the overall view, only vehicle-treated gonad-intact animals exhibited 
continual PSA increases over time. (B) Onset of PSA reduction below the limit of detection (0.5 
ng/ml) by each treatment is shown and the differences are analyzed by log-rank multiple comparison 
test versus ORX treatment. Vehicle control (dashed diamond), ORX (dashed cross), TAK-683 1.4 
nmol/kg/day (closed triangle), TAK-683 7 nmol/kg/day (closed circle), leuprolide 1.4 nmol/kg/day 
(open triangle), leuprolide 7 nmol/kg/day (open circle). Data in A and B are shown in mean + S.D. 
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Chapter 3: Chronic administration of the Kisspeptin Analogue 
KISS1-305 or the Investigational Agent TAK-448 Suppresses 
Hypothalamic Pituitary Gonadal Function and Depletes Plasma 
Testosterone in Adult Male Rats 
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Results 
In this chapter, I will describe the mechanism of the testosterone lowering effect of kisspeptin agonist 
analogues under chronic administration. 
 
Effect of Chronic Administration of KISS1-305 in Male Rats 
I studied the effect of chronic administration of the kisspeptin analogue KISS1-305 (4 nmol/h) in male 
rats. Both plasma T and LH levels were markedly increased on day 1 following initiation of dosing and 
dramatically decreased thereafter to the lower limit of detection (LH: 0.08 ng/mL, T: 0.04 ng/mL) by 
day 6 (Fig. 14A-B), suggesting suppression of pituitary-gonadal functions. Similarly, 4 and 8 hours 
following KISS1-305 administration c-Fos-ir expression in GnRH neurons within the region of the 
OVLT and aPOA was significantly increased but returned to normal levels by 24 h (Fig. 14C-J and 
Table 7), suggesting that the GnRH neurons became desensitized to KISS1-305 stimulation as a 
consequence of chronic exposure. I also found that chronic administration of KISS1-305 reduced the 
number of GnRH-ir neurons both at 24 h and day 6 (Table 7), suggesting the depletion of releasable 
GnRH pools as a consequence of the chronic administration of the kisspeptin analogue.  
 
Table 7 Summary of GnRH and c-Fos immunoreactivity after the initiation of chronic 
administration of KISS1-305 
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 Effect of chronic s.c. administration of KISS1-305 in male rats Fig. 14
KISS1-305 or vehicle was chronically administered to male rats, and plasma LH (A) and T (B) levels 
were determined at 4, 8, 24 h, and 6 days after the initiation of dosing. Data shown are mean + SD (n 
= 3). * and ** indicate P < 0.05 and 0.01 versus vehicle either by Student’s or Aspin-Welch t-test. 
(C-J) Representative photographs of GnRH (green) and c-Fos (red) IHC. Observation at 4 h (C, D), 8 
h (E, F), 24 h (G, H), and 6 days (I, J) after the initiation of either vehicle (C, E, G, I) or KISS1-305 (D, 
F, H, J). Arrows and arrowheads indicate c-Fos positive and c-Fos negative GnRH neuronal bodies, 
respectively.  
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LH Release after Chronic Administration of Kisspeptin Analogues 
To explore the mechanism of action underlying the effect of lowering T and gonadotropin by kisspeptin 
analogues, I first studied the LH-releasing response to a bolus administration of KISS1-305 (100 
nmol/kg) or leuprolide (100 nmol/kg) in rats that had received a 6-day chronic administration of 
KISS1-305 (2 nmol/h), leuprolide (2 nmol/h), or vehicle. Bolus KISS1-305 induced LH release in 
vehicle-treated rats, but not in rats treated with KISS1-305 or leuprolide (Fig. 15A). In contrast, bolus 
leuprolide increased LH levels in both vehicle- and KISS1-305-treated rats, but not in leuprolide-treated 
rats (Fig. 15A). These findings suggest that chronic administration of the GnRH analogue leuprolide 
desensitizes the pituitary to further GnRH exposure, while chronic KISS1-305 does not desensitize the 
pituitary to GnRH stimulation. This also suggests that the gonadotropin-lowering effect of kisspeptin 
analogues is not due to desensitization of the pituitary to GnRH but rather reflects diminished GnRH 
release from the hypothalamus in response to chronic exposure to kisspeptin analogues. Following 
6-day chronic KISS1-305 administration, I also evaluated the effect of another GnRH secretagogue, 
NMDA, on plasma LH levels, and found that a single bolus s.c. administration of NMDA (30 mg/kg) 
failed to elevate plasma LH levels (Fig. 15B) at 15 minutes after NMDA dosing.  
 
 LH release after 6-day chronic administration of KISS1-305  Fig. 15
(A) After 6-day chronic administration of vehicle, KISS1-305 (2 nmol/h), or leuprolide (2 nmol/h), 
animals received a bolus s.c. administration of KISS1-305 (100 nmol/kg) or leuprolide (100 nmol/kg) 
at time 0. Data shown are mean + SD (n = 6-8). * indicates P < 0.01 by paired t-test (0 versus 120 
minutes). (B) After 6-day chronic administration of vehicle or KISS1-305, animals received a bolus s.c. 
administration of NMDA (30 mg/kg) or saline. Plasma LH levels were determined 15 minutes after the 
NMDA administration (n = 8). The differences between vehicle- and NMDA-treatment were analyzed 
by Aspin-Welch t-test.  
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This blood sampling point (15 min) was chosen based on results from a pilot experiment (Fig. 16). 
NMDA induces c-Fos-ir proteins in the OVLT-aPOA area as shown in KISS1-305 naïve animals (Fig. 
17). 
 
 
 Effect of NMDA on plasma LH levels in intact male rats Fig. 16
Plasma LH levels peaked at 15 min after s.c. NMDA administration (30 mg/kg) in male Crl:CD(SD) 
rats. Data shown are mean ± SD (n = 3). 
 
 
 Effect of NMDA on c-Fos-ir expression. Fig. 17
Representative photographs (n = 3) showing c-Fos-ir expression around the region of the OVLT. 
NMDA administration induced c-Fos-ir expression in both 6-day vehicle and 6-day KISS1-305 treated 
rats. 
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Effect of Chronic Administration of Kisspeptin Analogues on the Hypothalamic GnRH Neuron 
Activity 
My data in Fig. 14 suggested that chronic exposure of GnRH neurons to kisspeptin analogues 
transiently induced c-Fos expression. Therefore, I studied whether GnRH neurons in rats that were 
chronically treated with KISS1-305 remained responsive to high-dose bolus KISS1-305. These studies 
employed IHC techniques to monitor c-Fos expression in target neurons. After a 3-week chronic 
administration of KISS1-305 (2 nmol/h), a single s.c. injection of KISS1-305 (100 nmol/kg) induced 
expression of c-Fos-ir in GnRH neurons, while injection of vehicle alone did not (representative 
photomicrographs are shown in Fig. 18). Similar results were obtained from multiple independent 
experiments (data not shown). These findings suggested that GnRH neurons still maintained their 
responsiveness to excessive kisspeptin stimuli in terms of c-Fos induction following chronic KISS1-305 
administration.  
 
 Effect of bolus KISS1-305 injection on IHC of c-Fos and GnRH in animals treated with Fig. 18
KISS1-305 for 3 weeks  
Representative photographs of c-Fos (red) and GnRH (green) immunoreactivity in the aPOA at the 
level of the OVLT are shown. Male rats were chronically administered either vehicle (A, C) or 
KISS1-305 (B, D) for 3 weeks, followed by a single administration of either vehicle (A, B) or 
KISS1-305 (C, D). Arrows and arrowheadindicate c-Fos positive and c-Fos negative GnRH neuronal 
bodies, respectively. 
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I evaluated Kiss1, Kiss1r, and Gnrh mRNA expression in rats that were treated with chronic 
KISS1-305 to determine if mRNA levels of these associated proteins were altered. Hypothalamic Kiss1 
mRNA levels were significantly upregulated after chronic administration of KISS1-305 for 3 weeks (Fig. 
19A), most likely reflecting the reduction of circulating T (13). Of interest, Kiss1r mRNA and Gnrh 
mRNA levels were essentially unchanged under these conditions (Fig. 19B and C). Finally, I assessed 
hypothalamic protein levels of GnRH, and found a significant reduction in hypothalamic GnRH at 3 
weeks (Fig. 19D). This reduction in hypothalamic GnRH supports my finding that there is a reduction of 
the number of GnRH-ir neurons as a consequence of chronic dosing with KISS1-305 (Table 7 and Fig. 
14).  
 
 
 Effect of chronic administration of kisspeptin analogues on hypothalamic Kiss-1, Kiss1r, Fig. 19
Gnrh mRNA expression levels and GnRH peptide contents 
Effect of chronic administration of KISS1-305 for 3 weeks on Kiss-1 (A), Kiss1r (B), Gnrh (C) mRNA 
levels and GnRH peptide contents (D). Data shown are mean + SD (n = 4) for relative values versus 
vehicle (vehicle = 1), * and ** indicate P < 0.05 and 0.01 versus vehicle, respectively, either by 
Student’s or Aspin-Welch t-test. 
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Effect of Chronic Administration of the Novel Kisspeptin Analogue TAK-448 on the HPG Axis 
I have designed and developed a novel, investigational, nonapeptide derivative of KISS1-305, 
designated TAK-448 (30). Chronic administration of TAK-448 (0.1 nmol/h) depleted plasma T levels 
below 0.04 ng/mL in male rats both at 1 and 4 weeks (Fig. 20A), demonstrating that this dose of 
TAK-448 was as effective at lowering T levels as KISS1-305 (2 nmol/h) and readily achieved chemical 
castration status in male rats. Chronic administration of TAK-448 achieved testosterone depletion as 
rapid as KISS1-305 but at a lower dose. Consequently, studies were initiated employing TAK-448 to 
better define the impact of kisspeptin analogue exposure on hypothalamic-pituitary functions. In these 
experiments I compared hypothalamic GnRH peptide content, Gnrh mRNA expression levels, plasma 
FSH and LH levels, and pituitary protein or mRNA levels for FSH and LH in rats treated with TAK-448 
(0.1 nmol/h) to that observed following exposure to leuprolide (0.3 nmol/h) or ORX (Fig. 20B-I). In 
agreement with my observations following the chronic administration of KISS1-305, chronic 
administration of TAK-448 significantly reduced hypothalamic GnRH content at both 1 and 4 weeks. In 
contrast, ORX or leuprolide treatment showed a significant reduction only after 4 weeks of therapy (Fig. 
20B). Gnrh mRNA expression levels were unchanged by any treatment (Fig. 20C).  
ORX elevated plasma FSH and LH levels both at 1 and 4 weeks (Fig. 20D and G), and pituitary 
gonadotropin protein as well as mRNA levels were also elevated by 4 weeks (Fig. 20E, F, H and I), 
suggesting modulation of steroidal negative feedback and compensatory activation of 
hypothalamic-pituitary functions. In contrast, chronic TAK-448 administration significantly reduced 
plasma levels of FSH and LH at both 1 and 4 weeks, which were lower than those by leuprolide 
treatment (Fig. 20D and G). This effect of TAK-448 was associated with significant reduction of 
pituitary FSH contents and Fshb and Lhb mRNA expression levels both at 1 and 4 weeks, and that of LH 
contents at 4 weeks (Fig. 20E, F, H and I). Leuprolide treatment significantly reduced plasma LH levels 
only at 4 weeks, and FSH levels at 1 and 4 weeks (Fig. 20D and G). Further, leuprolide administration 
dramatically depleted both FSH and LH protein and mRNA levels at 1 and 4 weeks (Fig. 20E, F, H and 
I). In other words, TAK-448 treatment decreased plasma LH and FSH levels more rapidly and 
effectively, with comparative reduction in the pituitary Fshb and Lhb mRNA levels with less apparent 
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reduction in the pituitary FSH and LH contents, than leuprolide treatment. 
 
 
 Effect of chronic administration of TAK-448 on HPG axis functions Fig. 20
After 1 or 4 weeks post-ORX, or treatment with vehicle, TAK-448 (0.1 nmol/h), or leuprolide (0.3 
nmol/h), plasma T levels (A), relative hypothalamic GnRH contents (B) Gnrh mRNA levels (C), 
plasma FSH (D) and LH (G) levels, relative pituitary FSH (E) and LH (H) contents, and relative 
pituitary Fshb (F) and Lhb (I) mRNA levels were examined. Data shown are mean + SD (n = 5 for 1 
week, n = 10 for 4 weeks). Statistically significant differences at each time point were observed 
between same letters with different numbers of apostrophe (e.g. a versus a’ versus a’’ are significantly 
different) by Steel-Dwass multiple comparison test.  
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Discussion 
In this study, I first revealed the robust stimulatory effect of kisspeptin agonist on ovulation induction 
in the rat. The gonadotropin releasing effect of kisspeptin was potent enough to induce full ovulation 
in female rats. This result suggests that Kp-54 induces biologically active LH release, and that the 
amount of released LH is sufficiently high to induce ovulation in the model. Such an explosive LH 
release is rather surprising and physiologically uncharacteristic in the normal male, and to my 
knowledge Kp-54 is the first reported peptide to be capable of producing this effect. This stimulatory 
effect was observed regardless gender differences (male and immature female rats) or hormonal milieu 
(immature female rats with or without follicular maturation). Immunohistochemical analysis revealed 
that almost 60% of GnRH neurons were c-Fos-positive. This is comparable to data reported for the 
preovulatory or steroid-induced LH surge that occurs in female rats (Lee et al., 1990; Attardi et al., 
1997), suggesting that the observed numbers of activated GnRH neurons account for the 
Kp-54-induced increase in plasma LH. On the other hand, Kp-54 did not potentiate gonadotropin 
release in monolayer-cultured rat pituitary cells. Therefore, I hypothesize that in rats, peripherally 
administered Kp-54 induces the secretion of hypothalamic GnRH, which in turn elicits gonadotropin 
release. 
In accordance with these findings, three independent studies from de Roux et al., Seminara et 
al., and Funes et al. demonstrated functional defects in KISS1R in human or mice resulted in the 
defective onset of puberty and suggested critical contribution of kisspeptin/KISS1R system in 
controlling the reproductive functions (de Roux et al., 2003; Funes et al., 2003; Seminara et al., 2003). 
Following these reports including my own, numbers of evidences demonstrated that 1) the existence of 
kisspeptin neurons (Kinoshita et al., 2005; Smith et al., 2005a; Smith et al., 2005b; Adachi et al., 
2007; Ramaswamy et al., 2008), 2) the expression of KISS1R in the GnRH neurons (Irwig et al., 
2004; Han et al., 2005; Messager et al., 2005; Liu et al., 2008; Pielecka-Fortuna et al., 2008), 3) 
depolarization and neural firing of GnRH neurons by kisspeptin in ex vivo experiments (Han et al., 
2005; Liu et al., 2008; Pielecka-Fortuna et al., 2008), and all of which strongly suggests that 
kisspeptin directly activate GnRH neurons, and supports my hypothesis that the stimulatory effect of 
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kisspeptin reflects the important feature of its physiological functions. It has not been still elucidated 
whether KISS1R is expressed on GnRH neural terminals, which locate outside of the blood brain 
barrier (BBB), or on GnRH perikarya, which locate inside of the BBB, or both due to the lack of 
reliable antibody against KISS1R. Available evidences have suggested that both can be considered, 
and further studies are required to adequately reveal the anatomical distribution of KISS1R in the 
brain (Kinoshita et al., 2005; d'Anglemont de Tassigny et al., 2008; Herde et al., 2011). Also, 
kisspeptin has shed light on the mechanism of steroid hormonal positive and negative feedback 
machinery within the hypothalamus. As described in the Introduction section, the activity of GnRH 
neurons is regulated by steroid hormones in a positive (i.e. pre-ovulatory GnRH surge) and negative 
(i.e. GnRH pulses) manner. Given that GnRH neurons do not express reliable steroid hormone 
receptors (Nishihara et al., 1999), historical evidences have strongly suggested the existence of GnRH 
neural afferents which express steroid hormone receptors and critically regulate GnRH release. 
Subsequent studies have revealed that, especially in rodents, there are two populations of kisspeptin 
neurons; one is within the arcuate nucleus (ARC) and the other is around the anteroventral 
periventricular nucleus (AVPV) (Fig. 1). The kisspeptin mRNA and protein expressions within the 
ARC Kp neurons have been shown to be increased and decreased by steroid hormone withdrawal and 
supplementation, respectively, suggesting ARC Kp neurons are the acceptor of steroid hormone 
negative feedback effect (Smith et al., 2005a; Smith et al., 2005b; Adachi et al., 2007). On the other 
hand, the AVPV kisspeptin neurons have been predominantly determined in female rats/mice and 
kisspeptin expressions are increased/decreased by the supplementation/withdrawal of estradiol, 
suggesting that the AVPV kisspeptin neurons are the acceptor of estradiol positive feedback effect and 
also female specific (Smith et al., 2005a; Smith et al., 2005b; Adachi et al., 2007). Also, the 
expression of steroid hormone receptors (ER, AR) has been demonstrated in kisspeptin neurons (Smith 
et al., 2005a; Smith et al., 2005b; Adachi et al., 2007). Thus, the currently most accepted hypothesis is 
that kisspeptin neurons critically regulate both GnRH pulses and surge as GnRH afferents (Fig. 21). 
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 Kisspeptin play a pivotal role in controlling GnRH release Fig. 21
In rodents, two distinct populations of kisspeptin neurons have been identified, one is the ARC 
kisspeptin neurons which are believed to receive steroid hormone negative feedback. The other is the 
AVPV kisspeptin neurons which are specific to female animals and receiving estradiol positive 
feedback. 
 
To more fully understand the effects of kisspeptin analogues, I then characterized 
pharmacological profiles of kisspeptin agonist analogues, and the effect of both repeated daily s.c. 
injections and continuous s.c. administrations in male rats. In vitro experiments demonstrated that both 
TAK-448 and TAK-683 are potent agonists for rat KISS1R, and TAK-683 showed slightly more potent 
in vitro receptor binding and agonistic activities than TAK-448. Recently it has been recognized that 
kisspeptin also interacts with neuropeptide FF receptors especially with NPFFR1 rather than NPFFR2, 
and RF-amide related peptide (RFRP)-NPFFR1 system has been suggested to act as GnRH inhibitory 
hormone (GnIH) (Oishi et al., 2011). Several studies have demonstrated that C-terminal RF-amide 
structure is important for interacting with NPFFR1/2 and substitution of the C-terminal Phe with other 
amino acids such as Tyr or Trp attenuated agonist activity or receptor binding affinity(Mollereau et al., 
2002; Engstrom et al., 2003; Yoshida et al., 2003; Findeisen et al., 2011). I also observed a similar 
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attenuated agonistic effect of rat Kp-10 with RY-amide structure compared to human Kp-10 with 
RF-amide structure (data not shown). Though it is very unlikely that TAK-448 and TAK-683, both 
having Arg(Me)-Trp-amide structure, potently interact with NPFFRs, additional in vitro studies are 
required to address this possibility. In vivo settings, TAK-448 showed better pharmacokinetic profiles 
than TAK-683 in my subcutaneous infusion protocol, and required dose of TAK-448 for complete 
testosterone suppression and profound reductions in weights of genital organs was lower than that of 
TAK-683. This superiority of TAK-448 over TAK-683 in vivo may be attributed to this better 
pharmacokinetic profiles or target engagement (i.e. GnRH neurons) given that TAK-683 showed better 
in vitro profiles than TAK-448. Further studies especially focusing on pharmacokinetic profiles of 
these compounds including tissue distribution such as the hypothalamus would be helpful to answer to 
this question.  
In this study, I evaluated the effect of both repeated daily subcutaneous injections and 
continuous subcutaneous administrations in male rats, and found that both regimens eventually 
suppressed male reproductive functions as evidenced by reductions in testosterone and weights of 
genital organs. In a once-daily s.c. injection study, the animals became insensitive to bolus TAK-448 
and TAK-683 injection in terms of LH and testosterone releases at 4h on Days 4 and 7, suggesting the 
desensitization to exogenous kisspeptin analogues. Reductions in baseline testosterone levels (i.e. 0h 
on Days 4 and 7) were also observed both by TAK-448 and TAK-683 treatments. At 8 μmol/kg of 
TAK-448 and TAK-683, both 0h and 4h testosterone levels were suppressed below the limit of 
quantification (0.04 ng/ml), suggesting that the 8 μmol/kg was the minimum effective once-daily dose 
of TAK-448 and TAK-683 for complete suppression of plasma testosterone levels in male rats. In this 
study I could not observe statistically significant reductions in baseline plasma LH levels, except for at 
0h on Day 7 with 8 μmol/kg of TAK-448 the dose which was associated with significantly reduced 
testicular weights. Additional studies such as observations of LH pulses are required to clearly 
demonstrate the effect on baseline plasma LH levels, as recently observed in goats after chronic 
infusion of TAK-683 (Tanaka et al., 2013). Chronic administration of the kisspeptin analogue, 
KISS1-305, at doses of 2 nmol/h or greater, induced an initial brief elevation in plasma LH and T levels, 
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followed by rapid reduction in plasma T that remained at decreased levels throughout the 4-week study 
period. Genital organ weights also were markedly reduced as a consequence of chronic KISS1-305 
administration. The infusion rates of TAK-448 and TAK-683 required to reduce plasma testosterone to 
below the limit of detection (0.04 ng/ml) throughout the 4-week dosing period were ≥ 0.7 nmol/kg/day 
and ≥ 2.1 nmol/kg/day; at those infusion rates, weights of the genital organs were reduced to the 
castrate levels. Therefore these doses can be considered as the minimum effective continuous doses of 
TAK-448 and TAK-683 in male SD rats, and the results suggest that the continuous administration 
regimen is a simpler and more convenient method to suppress male reproductive functions in rats. 
Thus, TAK-448 and TAK-683 have basically the same in vivo profiles but required dose of TAK-448 is 
smaller than TAK-683 for testosterone suppression. Currently both TAK-448 and TAK-683 have been 
evaluated in human male, and continuous subcutaneous infusion of TAK-448 (≥ 0.1 mg/day) achieved 
castration (i.e. serum testosterone levels ≤ 50 ng/dL) at lower doses than TAK-683 (2 mg/day) (Scott 
et al., 2013; MacLean et al., 2014). In this study I did not determine pharmacokinetic profiles of 
TAK-448 and TAK-683 after single subcutaneous administration. I need to evaluate other dosing 
regimens such as twice daily administration to compare repeated dosing regimen with continuous 
infusion regimen precisely.  
Others have previously conducted repetitive or continuous administration of the natural 
kisspeptins Kp-10 and Kp-54 in rodents, monkeys, and humans. In rodents, continuous 13-day 
administration of Kp-54 (50 nmol/day) in male rats suppressed plasma testosterone levels and genital 
organ weights (Thompson et al., 2006). Hourly injections of Kp-10 (2 μg/injection, [approximately 1.5 
nmol/injection]) in juvenile male monkeys led to a train of repetitive LH elevations, while continuous 
infusion of Kp-10 (400 μg/h, [approximately 300 nmol/h]) in adult male monkeys desensitized the 
responsiveness of the hypothalamic-pituitary system against exogenous Kp-10 (Plant et al., 2006; 
Seminara et al., 2006; Ramaswamy et al., 2007). In the present study, both once-daily s.c. injection 
and continuous administration of TAK-448 and TAK-683 suppressed the pituitary-gonadal functions in 
male rats. Testosterone reduction by continuous administration of TAK-448 and TAK-683 was more 
evident than that caused by continuous 13-day Kp-54 infusion (Thompson et al., 2006). Also, Tanaka 
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et al. previously have shown that continuous administration of kisspeptin analogues in male monkeys 
results in more pronounced testosterone suppression than continuous administration of Kp-10 
(Ramaswamy et al., 2007; Tanaka et al., 2010). Better metabolic stability of TAK-448 and TAK-683 
compared to the natural kisspeptins may explain the analogue’s more pronounced suppression of the 
hypothalamic-pituitary-gonadal functions. 
In comparison to the GnRH agonist analogue leuprolide, kisspeptin agonist analogues 
produced more rapid and profound reductions in plasma testosterone levels as well as weights of 
genital organs. Clinically, GnRH analogue-based ADT is widely used in prostate cancer therapy, but T 
flare, which can be observed in the first week of therapy, may be associated with unfavorable therapeutic 
outcomes (Bubley, 2001). It has also been suggested that lower serum testosterone levels leads to better 
prognosis including overall survival (Perachino et al., 2010). My study shows that chronic 
administration of kisspeptin analogues was more effective than leuprolide in terms of rapid and dramatic 
reductions in plasma T and weights of genital organs. Therefore, by virtue of their ability to profoundly 
reduce T, kisspeptin analogues such as TAK-448 may hold promise as a novel, more efficacious ADT 
than the current GnRH analogue-based prostate cancer therapies. In addition to GnRH agonist 
analogues, a peptidic GnRH antagonist analogue, degarelix, has been approved for prostate cancer 
treatment, but I did not compare the efficacy of kisspeptin analogues to GnRH antagonists. Additional 
studies would be helpful to understand the therapeutic potential of kisspeptin analogues in comparison 
to GnRH agonist and antagonist analogues. 
Next I evaluated the antitumor effect of kisspeptin analogues in the JDCaP 
androgen-dependent prostate tumor model (Kimura et al., 2009) in nude rats, and TAK-683 was used 
as a representative kisspeptin analogue in this study because of technical availability at the time of 
study conducted. I used serum PSA as a biomarker for tumor growth instead of direct measurement of 
tumor size since the tumor was implanted under renal capsule and I could not observe the tumor 
volume directly. Bilateral orchiectomy rapidly reduced serum PSA levels below the lower detection 
limit; the PSA nadir was observed in all rats within 7 days after treatment, suggesting that this JDCaP 
model showed good androgen dependency as expected from the original observation in mice (Kimura 
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et al., 2009). Analysis of the time course of PSA reduction in this model showed that TAK-683 and 
ORX result in more rapid PSA reduction compared with leuprolide at the doses tested. Although I did 
not measure testosterone levels in this study, it is plausible that the differences in the time to onset of 
PSA reduction arose from differences in time to onset of testosterone suppression. Since I did not 
evaluate objective tumor responses as described above, additional examinations such as tumor 
morphology, AR expressions are required to further understand potential superiority of TAK-683 over 
leuprolide. Recently it has been shown that the JDCaP tumor line can acquire hormone resistance in 
mice (Nakata et al., 2010). Longer-term evaluation or studies in other prostate cancer model would 
provide better understanding of potential therapeutic benefits of kisspeptin analogues in prostate 
cancer treatment. Thus, I have demonstrated that repetitive or continuous administration of kisspeptin 
analogues, TAK-448 and TAK-683, rapidly suppresses male reproductive functions in rats. Compared 
to leuprolide, continuous administration of TAK-448 and TAK-683 resulted in shorter testosterone 
flare, more rapid onset of testosterone suppression, and greater reduction of both testosterone levels 
and weights of genital organs in male rats. Continuous administration of kisspeptin analogues also 
produced more rapid PSA suppression than leuprolide in a rat model of androgen-dependent prostate 
cancer. These results suggest that kisspeptin analogues may hold promise as a novel treatment option 
for several hormone-related diseases including prostate cancer. Further studies, especially in humans, 
will provide more precise understanding of the clinical significance and therapeutic potential of 
TAK-448 and TAK-683. 
The last part of this Thesis was aimed to elucidate the neuroendocrine and physiological effects 
associated with the chronic administration of kisspeptin analogues or a GnRH analogue in male rats. 
To clarify the cellular events associated with these observations, I examined c-Fos-ir and GnRH-ir 
within the hypothalamic region as well as pituitary responsiveness to exogenous GnRH analogue 
stimulation. The administration of KISS1-305 was associated with transiently-increased expression of 
c-Fos-ir in a large proportion of GnRH neurons within the region of the OVLT and aPOA, anatomical 
regions possessing a large number of neurons responsible for the release of GnRH from the median 
eminence(Silverman et al., 1987; Merchenthaler et al., 1989). Following chronic kisspeptin analogue 
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dosing, c-Fos expression and the number of GnRH-ir neurons decreased in parallel with a reduction in 
plasma LH and T levels. These results highlight two important mechanistic impacts of kisspeptin 
analogue treatment on the hypothalamus. First, the initiation of chronic kisspeptin analogue 
administration strongly but transiently activates GnRH neurons and appears to induce marked GnRH 
release, which correlates with elevated LH and T (flare) observed on the first day. Secondly, within 24 
hours, GnRH neurons become desensitized to further kisspeptin stimulation, at least in terms of 
analogue-induced c-Fos expression. This second effect is also associated with drastic reduction in 
GnRH-ir positive neurons. This observation suggests that chronic exposure to kisspeptin analogues 
desensitizes GnRH neurons to chronic stimuli from kisspeptin analogues and exhausts GnRH neuronal 
pools. Either of these effects, alone or combined, induces a rapid reduction in plasma T and LH levels.  
On the other hand, following chronic kisspeptin analogue administration, pituitary 
responsiveness to the GnRH analogue leuprolide was maintained. Indeed, following a 1-week exposure 
to KISS1-305, a single bolus injection of leuprolide (but not KISS1-305) elevated plasma LH levels. I 
also examined pituitary and plasma gonadotropin levels. TAK-448 and leuprolide reduced pituitary and 
plasma FSH and LH levels in different ways. Leuprolide rapidly depleted pituitary gonadotropin mRNA 
and protein levels as early as 1 week but required longer exposure (4 weeks) to decrease plasma LH 
levels. FSH and LH depletion from the pituitary by leuprolide at 1 week can be primarily attributed to a 
substantial and prolonged gonadotropin release, followed by desensitization of the pituitary. It can also 
be speculated that leuprolide caused continuous low but detectable FSH and LH release at 4 weeks as 
evidenced by detectable plasma FSH, LH, and T levels. In contrast to leuprolide, TAK-448 caused a less 
apparent but still significant reduction in pituitary FSH content at 1 and 4 weeks and LH content at 4 
weeks, while pituitary Fshb and Lhb mRNA levels as well as plasma gonadotropin levels were 
downregulated by 1 week. Since both gradual reduction in gonadotropin contents and apparent decrease 
in Fshb and Lhb mRNA levels are well explained by reduced GnRH pulses (McDowell et al., 1982; 
Young et al., 1983; Kaiser, 1997), my findings in kisspeptin analogue-treated animals supports the 
contention that pulsatile GnRH release from the hypothalamus is reduced or disrupted by chronic 
TAK-448 treatment by 1 week, leading to inhibition of pituitary function. 
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As discussed above, GnRH neurons appear to be desensitized following continuous stimulation 
by kisspeptin analogues. These findings support previous studies in monkeys (Seminara et al., 2006; 
Ramaswamy et al., 2007) suggesting that the endocrinologic effects of chronic kisspeptin analogue 
administration may be similar in different species. Several lines of evidences have suggested that the 
desensitization of GPCR may involve receptor internalization and subsequent reduction in cell surface 
GPCR, uncoupling to G-proteins, altered downstream signaling, or ubiquitination (Bianco et al., 2011; 
Millar et al., 2012). In addition to these proposed mechanism, my study in Chapter 3 also proposes a 
hypothesis that the desensitization does not mean "the complete abolishment of the KISS1R 
responsiveness to kisspeptin" but actually suggest "the attenuation of the KISS1R responsiveness to 
kisspeptin", as c-Fos expression was induced in GnRH neurons by bolus KISS1-305 administration 
despite the fact that these animals had been chronically treated with lower dose KISS1-305. Indeed, 
Kiss1r mRNA levels were not downregulated following the 3-week chronic administration regimen. 
These findings imply that the chronic administration of kisspeptin analogues probably attenuates, but 
does not completely abolish, GnRH neuronal responsiveness to exogenous kisspeptin analogue 
stimulation, and, in turn, hinders endogenous kisspeptin signaling, while endogenous kisspeptin 
neuronal activity was likely enhanced after chronic administration of kisspeptin analogues as evidenced 
by upregulation of Kiss1 mRNA levels and its consequent impact on the endogenous neural pathway. 
This concept may be generalized to the other GPCRs. For example, as also discussed above, it can also 
be speculated that continuous administration of the GnRH analogue leuprolide caused continuous low 
but detectable FSH and LH release at 4 weeks as evidenced by detectable plasma FSH, LH, and T 
levels. This hypothesis requires remaining KISS1R on the GnRH neural surface under the continuous 
exposure to kisspeptin agonists, and may be supported by the recent findings which suggest dynamic 
KISS1R recycling and intracellular KISS1R pool which may enable the cells to be responsive to the 
ligand under the chronic exposure (Bianco et al., 2011; Babwah et al., 2012).  
Chronic administration of kisspeptin analogues reduced hypothalamic GnRH peptide contents 
during the entire 4-week dosing regimen. This may explain why KISS1-305-treated rats showed no LH 
release even after high doses of KISS1-305 or NMDA. However, it is unclear whether the decreased 
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GnRH content alone has a significant impact on GnRH pulse generation, because highly decreased 
GnRH levels were also observed in ORX rats that had elevated pituitary function as evidenced by 
increased pituitary and plasma gonadotropin levels. Indeed, reduction of GnRH after castration can be 
explained by maximized pulsatile GnRH release due to the lack of T negative feedback on GnRH 
neurons. In contrast, the more rapid and sustained GnRH reduction with suppressed pituitary function 
associated with kisspeptin analogue treatment can be explained by two processes. The first process is an 
acute effect: Depletion of releasable GnRH resulting from substantial GnRH release at dosing initiation, 
as discussed above. The second process is a long-term effect: As Gnrh mRNA levels were unchanged 
after the chronic administration of kisspeptin analogues, and it is unlikely that kisspeptin analogues 
affect GnRH translation or processing since both Kiss1 and Kiss1r disruption do not affect hypothalamic 
GnRH content (Messager et al., 2005; d'Anglemont de Tassigny et al., 2007), the most plausible 
explanation accounting for decreased hypothalamic GnRH content without changing Gnrh mRNA 
expression is that GnRH neurons are continuously releasing GnRH, albeit at very low levels without 
detectable increase of c-Fos expression in GnRH neurons, in response to continuously-administered 
kisspeptin analogues. This continuous stimulation of GnRH neurons and the consequent continuous 
low-level release of GnRH may also disrupt GnRH pulses caused by redundant neuronal pathways, as 
suggested by Chan et al. (Chan et al., 2009). In this case, these proposed redundant pathways cannot 
recover or participate in hypothalamic-pituitary functioning. Direct and highly sensitive determination 
of GnRH release from the hypothalamus or monitoring of GnRH neuronal electrophysiological activity 
would be required to confirm this explanation, since c-Fos-ir induction in GnRH neurons may not 
always correlate with GnRH release. 
Thus, my findings suggest that chronic administration of kisspeptin analogues suppresses 
intrinsic GnRH pulses and downstream pituitary-gonadal functions. This may be due to the attenuation 
of the responsiveness of GnRH neurons to endogenous kisspeptin stimulation and the stimulation of 
GnRH neurons to release low levels of GnRH continuously (Fig. 22), however further studies are 
required to exactly elucidate the status of GnRH neurons.  
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 Proposed mechanism of action Fig. 22
Kisspeptin analogue treatment results in strong activation of GnRH neurons , and substantial GnRH 
and LH/T release . Subsequent rapid attenuation of GnRH neuron responsiveness, which hinders 
endogenous kisspeptin input , and/or rapid reduction of GnRH contents  may explain abrupt LH/T 
reduction .  GnRH neuron responsiveness is not fully abolished , GnRH contents are not 
recovered , suggesting continuous leakage of GnRH . 
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Conclusions 
In conclusion, this study demonstrated that the novel peptide kisspeptin acts on the hypothalamic 
GnRH neurons and stimulates robust release of gonadotropins (FSH and LH), suggesting that 
kisspeptin/KISS1R system is the critical component of the HPG-axis by controlling the GnRH neurons. 
My study also demonstrated the potential application of kisspeptin agonist analogues as androgen 
dependent prostate cancer agents through the mechanism of desensitization of the GnRH neurons; 
more precisely attenuation of the responsiveness of KISS1R on the GnRH neurons to kisspeptin. 
Further studies are warranted to more precisely elucidate the physiological roles of kisspeptin and its 
clinical benefits. 
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